| | 5-HT3RA (n = 32) | Metoclopramide (n = 18) | p value |
|---|
TC | 27 (84.3%) | 4 (22.2%) | < 0.001 |
CC | 29 (90.6%) | 6 (33.3%) | < 0.001 |
CR | 29 (90.6%) | 6 (33.3%) | < 0.001 |
- 5-HT3RA [ramosetron (0.1 mg/body, orally) or granisetron (3 mg/body, intravenously)], or metoclopramide (5 mg/body, orally) was administered once per day from Day 1 (before initiation of azacitidine) to Day 7. TC was defined as no vomiting, no use of antiemetic rescue medication and no nausea. CC was defined as no vomiting, no use of antiemetic rescue medication and only grade 0–1 nausea. CR was defined as no vomiting, and no use of antiemetic rescue medication. Statistical difference was assessed by chi-squared test. 5-HT3RA, 5-HT3 receptor antagonist; CC, complete control; CR, complete response; TC, total control
